Atlas Trials

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Clinical trial NCT06326736 · RECRUITING

Trial details

NCT number
NCT06326736
Sponsor
Jinling Hospital, China
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2024-04-01
Primary completion
2025-12-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.